Last week the Centers for Medicare and Medicaid Services posted a tentative Physician Fee Schedule for 2023. Initial reactions from radiology were muted. That changed this Wednesday.

To subspecialize or not to subspecialize? That’s a crucial question for radiology trainees who are finishing their residency but have yet to settle on a lifelong career path.

CMS has released its highly anticipated tentative rule for governing the 2023 Medicare Physician Fee Schedule (MPFS). In turn, the American College of Radiology has posted a first-look summary focused on the schedule’s implications for medical imaging.  

The shortage of iodinated contrast media that has rattled U.S. radiology since early May didn’t come from nowhere.

Fewer than 40% of rural counties in the U.S. can offer residents any access to point-of-care ultrasound, while nearly 90% of their metropolitan counterparts have POCUS aplenty. 

An imaging OEM is teaming with a multi-omics diagnostics company to offer lung-cancer care teams lab data alongside radiologic findings and clinical histories.

One of the largest private health insurers in the U.S. has gone from considering hybrid PET/CT for cardiac indications “experimental/investigational” to displaying willingness to pay for the modality. 

A cancer-care technology company that was acquired by one of the world’s largest imaging OEMs a year ago has received an Investigational Device Exemption from the FDA.